Re: Anti-inflammatory Effects of Cocoa Consumption May Help Prevent Atherosclerosis
Monagas M, Khan N, Andres-Lacueva C, et al. Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. Am J Clin Nutr. 2009;90: 1144-1155.
Studies have indicated that dietary flavonoids may help
prevent coronary heart disease (CHD). Cocoa
and its products are a rich source of dietary flavonoids. The health benefits
of cocoa are related to the capacity to improve lipid profiles and insulin
sensitivity, lower blood pressure, reduce platelet activity and function, and diminish
endothelial dysfunction.1-3 Recent evidence has linked inflammation
with the initiation and progression of atherosclerosis. According to the
authors, few human trials have studied the anti-inflammatory effects of cocoa,
and those studies have reported contradictory results―either neutral effects or
single inflammatory biomarker changes, including endothelial-derived adhesion
molecules, proinflammatory cytokines, and high-sensitivity C-reactive protein
(hs-CRP). The authors conducted a randomized, crossover, controlled clinical
trial to assess chronic cocoa consumption in subjects at high-risk for CHD on
the expression of soluble adhesion molecules and proinflammatory cytokines associated
with early atherosclerosis stages.
The authors recruited 47 high-risk subjects who were
patients in the outpatient clinic of the Internal Medicine Department of the
Institut d’Investigació Biomèdica August Pi i Sunyer at the University of
Barcelona, Spain. Of those 47 recruits, 5 declined, leaving 42 (19 men and 23
women) participating subjects. Their mean age ± standard deviation was 69.7 ±
11.5 years. The subjects had diabetes mellitus or at least 3 or more of the
following risk factors: tobacco smoking, hypertension, plasma low-density
lipoprotein (LDL) cholesterol ≥160 mg/dL, plasma high-density lipoprotein (HDL)
cholesterol ≤35 mg/dL, obesity (body mass index ≥30), and/or family history of
premature CHD.
The study was a randomized, crossover, controlled clinical
trial of two 4-week periods. After a 2-week lead-in diet, half of the subjects
(who made up the C+M group) received two 20-g sachets of soluble cocoa powder
(Nutrexpa S.A.; Barcelona, Spain) per day (1 for breakfast and another for the
afternoon snack or after dinner) (total, 40 g per day) with 250 mL skim milk
each (total, 500 mL per day). The other half of the subjects was placed in the
M intervention group and consumed 500 mL skim milk per day with no cocoa. After
4 weeks, the interventions were switched between the 2 groups, for another
4-week period, with no washout period.
All subjects followed an isocaloric Mediterranean diet and
were asked to exclude all other cocoa-containing foods and to limit intake of
high polyphenol content foods like tea, red wine, vegetables, and fruit. At the
beginning of the study and after each intervention period, the subjects
completed a 3-day food record questionnaire. At baseline and after each
intervention, anthropometric and blood pressure measurements were recorded, and
fasting blood samples and a 24-hour urine specimen were collected.
Immunophenotyping of peripheral blood mononuclear cells was performed.
The authors report the following results:
·Body weight was slightly higher after the C+M
intervention than after the M intervention, with a mean increase of 0.50 kg
(P=0.013).
·No significant changes were observed in systolic and
diastolic blood pressure or in heart rate between the 2 interventions.
·Of the biochemical variables, serum concentrations of
fasting glucose, total cholesterol, LDL cholesterol, and triglycerides did not
change significantly after the 2 interventions. However, the HDL cholesterol
concentration was modestly higher after C+M intake (mean increase: 2.2 mg/dL,
P=0.033) than after M intake.
·The expression of the adhesion molecules on the
surface of monocytes, but not on T lymphocytes, was significantly lower for
very late activation antigen-4 (VLA-4) (P=0.005), CD40 (P=0.028), and CD36
(P=0.001) after C+M intake than after M intake.
·For the remaining molecules (lymphocyte
function-associated antigen-1 [LFA-1], Mac-1, and Sialil-Lewis X [SLex]),
no significant differences were observed on the monocyte or T lymphocyte
surfaces.
·Regarding changes in circulating inflammatory
markers, statistically significant lower concentrations of P-selectin (-10.8%,
P=0.007) and intercellular adhesion molecule-1 (ICAM-1) (-9.7%, P=0.007) occurred
with the C+M intervention than with the M intervention. Vascular cell adhesion
molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1)
concentration changes were lower but were not statistically significant.
E-selectin, interleukin-6 (IL-6), and hs-CRP concentrations remained almost
constant after C+M intake in comparison with M intake.
The authors cite other studies on consumption of various
cocoa products in which the outcomes are mixed and contradictory. They conclude
that the results of their study suggest that the common form of intake of cocoa
and its polyphenols in milk may modulate inflammatory mediators in patients at
high risk for cardiovascular disease. "These anti-inflammatory effects,
together with other previously reported effects, including those of
antioxidant, antiplatelet, and positive vascular effects, may contribute to the
overall benefits of cocoa consumption against atherosclerosis." The issue
of weight gain with cocoa use needs more in-depth study; those who use cocoa
products daily should incorporate an equivalent caloric reduction in their
normal diet.
―Shari
Henson
References
1Lamuela-Raventós RM, Romero-Pérez AI,
Andrés-Lacueva C, Tornero A. Review: health effects of cocoa flavonoids. Food Sci Technol Int. 2005;11:159-176.
2Ding EL, Hutfless SM, Ding X, Girotra
S. Chocolate and prevention of cardiovascular disease: a systematic review. Nutr Metab. 2006;3:1-12.
3Cooper KA, Donovan JL,
Waterhouse AL, Williamson G. Cocoa and health: a decade of research. Br J Nutr. 2008;99:1-11.